Insys Therapeutics Inc (INSY) 38.64 $INSY
Global Malignant Glioma Clinical Trials Review 2014
M2 - Tue Apr 15, 2:27AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5jwz85/malignant_glioma) has announced the addition of the "Malignant Glioma Global Clinical Trials Review, H1, 2014" report to their offering. Malignant Glioma Global Clinical Trials Review, H1, 2014" provides data on the Malignant Glioma clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Malignant Glioma. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Malignant Glioma. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies/Organisations Participating in Malignant Glioma Therapeutics Clinical Trials - Merck & Co., Inc. - Insys Therapeutics, Inc. - Eisai Co., Ltd. - Eli Lilly and Company - Sanofi - Tactical Therapeutics, Inc - GlaxoSmithKline plc - Celgene Corporation - Amgen Inc. - Advantagene, Inc. - National Cancer Institute - Duke University - Memorial Sloan Kettering Cancer Center - North American Brain Tumor Consortium - The University of Texas M. D. Anderson Cancer Center - UCLA's Jonsson Comprehensive Cancer Center - Northwestern University - NCIC Clinical Trials Group - European Organization for Research and Treatment of Cancer For more information visit http://www.researchandmarkets.com/research/5j...ant_glioma
Healthcare Companies Report Results, Patents, and Stock Movements - Analyst Notes on Puma Biotechnology, Alnylam, INSYS Therapeutics, Peregrine Pharmaceuticals, and VIVUS
PR Newswire - Thu Apr 10, 11:28AM CDT
Today, Analysts Review released its analysts' notes regarding Puma Biotechnology, Inc. (NYSE: PBYI), Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY), INSYS Therapeutics, Inc. (NASDAQ: INSY), Peregrine Pharmaceuticals Inc. (NASDAQ: PPHM), and VIVUS Inc (NYSE: ESC). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Nasdaq stocks posting largest percentage decreases
AP - Wed Apr 02, 5:16PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
New Haven Pharmaceuticals Appoints Larry Dillaha, M.D. as Executive Vice President Operations
PR Newswire - Wed Apr 02, 6:00AM CDT
New Haven Pharmaceuticals, Inc. (the "Company"
, a privately held specialty pharmaceuticals company, today announced the appointment of Larry Dillaha, M.D., to the newly-created position of Executive Vice President Operations. Dr. Dillaha joins the Company from Insys Therapeutics, Inc. (Nasdaq: INSY) where he served as Chief Medical Officer since April 2010.
Insys Therapeutics, Inc. [INSY] to Ring The NASDAQ Stock Market Opening Bell
GlobeNewswire - Tue Apr 01, 9:00AM CDT
What:
Stock Futures Look Favorable; Legg Mason, Novartis, Climb
at Investor's Business Daily - Mon Mar 31, 8:00AM CDT
Stock futures pointed firmly toward a positive open Monday, as the market prepared for the last trading day of March and the final session of the first quarter. Dow futures were nearly 64 points above fair market value. Nasdaq 100 futures were up a...
Insys Therapeutics Completes Three-for-Two Stock Split Through Stock Dividend
Marketwire - Mon Mar 31, 6:01AM CDT
Insys Therapeutics, Inc. (NASDAQ: INSY), a specialty pharmaceutical company with focus on supportive care products for cancer patients, today announced that the Company has completed its previously disclosed three-for-two stock split, effected through a stock dividend.
'Mad Money' Lightning Round: Marathon Petroleum's For Me
at The Street - Fri Mar 28, 5:00AM CDT
Cramer said to wait on Rite Aid, sell Infoblox and don't gamble on Wynn Resorts or Las Vegas Sands right now.
Jim Cramer's 'Mad Money' Recap: Wall Street Is Confused
at The Street - Thu Mar 27, 7:26PM CDT
Cramer says the market is so full of confusing cross-currents it has him wondering if there's something big around the corner.
Insys Therapeutics to Present at the 13th Annual Needham Healthcare Conference
Marketwire - Wed Mar 19, 3:30PM CDT
Insys Therapeutics, Inc. (NASDAQ: INSY) today announced that the Company will present at the 13th Annual Needham Healthcare Conference on April 8 - 9, 2014 at the Westin Grand Central in New York City.
Insys Therapeutics (INSY) Showing Signs Of A Dead Cat Bounce Today
at The Street - Tue Mar 18, 9:55AM CDT
Trade-Ideas LLC identified Insys Therapeutics (INSY) as a "dead cat bounce" (down big yesterday but up big today) candidate
Should You Believe Tesaro's Hype?
Todd Campbell, The Motley Fool - Motley Fool - Mon Mar 17, 1:30PM CDT
Tesaro's CEO Lonnie Moulder is likely unfazed by the company's eye popping volatility over the past few months. Moulder has a long history of navigating the inherent booms and busts common in emerging biotech. Luckily for Moulder's investors,...
Insider Trading Alert - INSY, RAI And ACGL Traded By Insiders
at The Street - Fri Mar 14, 10:45AM CDT
Stocks with insider trader activity include INSY, RAI and ACGL
Financial Results, FDA Reviews, and Share Price Movements - Analyst Notes on Insys, Oxygen Biotherapeutics, Acorda, Air Methods, and AcelRx
PR Newswire - Fri Mar 07, 7:00AM CST
Today, Analysts Review released its analysts' notes regarding INSYS Therapeutics, Inc. (NASDAQ: INSY), Oxygen Biotherapeutics, Inc. (NASDAQ: OXBT), Acorda Therapeutics, Inc. (NASDAQ: ACOR), Air Methods Corp. (NASDAQ: AIRM), and AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Has Insys Run Too Far Too Fast?
Todd Campbell, The Motley Fool - Motley Fool - Wed Mar 05, 5:30PM CST
Few investments have paid off as handsomely as Insys this past year. The company, which gets most of its sales from breakthrough pain treatment Subsys, has soared more than 700% in the past year. The excitement surrounding Insys has come as...
INSYS Therapeutics (INSY) Soars: Stock Adds 21.7% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Mar 05, 8:39AM CST
INSYS Therapeutics, Inc. was a big mover last session, as its shares rose just nearly 22% on the day.
Insys Therapeutics: Today's Big Biotech Winner
David Williamson, The Motley Fool - Motley Fool - Tue Mar 04, 6:52PM CST
Shares of Insys Therapeutics rose 20% today, after the company posted strong second-quarter results for its cancer-related pain medicine, Subsys. After operating at a loss last year, the 38% sales growth of the drug this year helped propel Insys...
Insys Q4 Earnings Beat Street; Stock Hits High
at Investor's Business Daily - Tue Mar 04, 2:44PM CST
Biotech Insys Therapeutics (INSY) soundly beat analysts' Q4 estimates and announced a stock split Tuesday, sending shares soaring more than 20% to a new high on the stock market today. The company's revenue totaled $40 million in the quarter vs. just...
Stocks Rally As Ukraine Fears Ebb; China Names Lead
at Investor's Business Daily - Tue Mar 04, 2:09PM CST
Fears of a conflict in Ukraine subsided -- at least for a day -- on Wall Street as stocks raced out of the gate and held strong gains with a little over one hour remaining in the session. The Nasdaq gained 1.6%, good for another 52-week high. The S&P...
Why Insys Therapeutics, Inc. Shares Skyrocketed
Sean Williams, The Motley Fool - Motley Fool - Tue Mar 04, 12:23PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Insys Therapeutics , a biopharmaceutical...
Global Malignant Glioma Clinical Trials Review 2014
M2 - Tue Apr 15, 2:27AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5jwz85/malignant_glioma) has announced the addition of the "Malignant Glioma Global Clinical Trials Review, H1, 2014" report to their offering. Malignant Glioma Global Clinical Trials Review, H1, 2014" provides data on the Malignant Glioma clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Malignant Glioma. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Malignant Glioma. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies/Organisations Participating in Malignant Glioma Therapeutics Clinical Trials - Merck & Co., Inc. - Insys Therapeutics, Inc. - Eisai Co., Ltd. - Eli Lilly and Company - Sanofi - Tactical Therapeutics, Inc - GlaxoSmithKline plc - Celgene Corporation - Amgen Inc. - Advantagene, Inc. - National Cancer Institute - Duke University - Memorial Sloan Kettering Cancer Center - North American Brain Tumor Consortium - The University of Texas M. D. Anderson Cancer Center - UCLA's Jonsson Comprehensive Cancer Center - Northwestern University - NCIC Clinical Trials Group - European Organization for Research and Treatment of Cancer For more information visit http://www.researchandmarkets.com/research/5j...ant_glioma
Healthcare Companies Report Results, Patents, and Stock Movements - Analyst Notes on Puma Biotechnology, Alnylam, INSYS Therapeutics, Peregrine Pharmaceuticals, and VIVUS
PR Newswire - Thu Apr 10, 11:28AM CDT
Today, Analysts Review released its analysts' notes regarding Puma Biotechnology, Inc. (NYSE: PBYI), Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY), INSYS Therapeutics, Inc. (NASDAQ: INSY), Peregrine Pharmaceuticals Inc. (NASDAQ: PPHM), and VIVUS Inc (NYSE: ESC). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Nasdaq stocks posting largest percentage decreases
AP - Wed Apr 02, 5:16PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
New Haven Pharmaceuticals Appoints Larry Dillaha, M.D. as Executive Vice President Operations
PR Newswire - Wed Apr 02, 6:00AM CDT
New Haven Pharmaceuticals, Inc. (the "Company"
, a privately held specialty pharmaceuticals company, today announced the appointment of Larry Dillaha, M.D., to the newly-created position of Executive Vice President Operations. Dr. Dillaha joins the Company from Insys Therapeutics, Inc. (Nasdaq: INSY) where he served as Chief Medical Officer since April 2010. Insys Therapeutics, Inc. [INSY] to Ring The NASDAQ Stock Market Opening Bell
GlobeNewswire - Tue Apr 01, 9:00AM CDT
What:
Stock Futures Look Favorable; Legg Mason, Novartis, Climb
at Investor's Business Daily - Mon Mar 31, 8:00AM CDT
Stock futures pointed firmly toward a positive open Monday, as the market prepared for the last trading day of March and the final session of the first quarter. Dow futures were nearly 64 points above fair market value. Nasdaq 100 futures were up a...
Insys Therapeutics Completes Three-for-Two Stock Split Through Stock Dividend
Marketwire - Mon Mar 31, 6:01AM CDT
Insys Therapeutics, Inc. (NASDAQ: INSY), a specialty pharmaceutical company with focus on supportive care products for cancer patients, today announced that the Company has completed its previously disclosed three-for-two stock split, effected through a stock dividend.
'Mad Money' Lightning Round: Marathon Petroleum's For Me
at The Street - Fri Mar 28, 5:00AM CDT
Cramer said to wait on Rite Aid, sell Infoblox and don't gamble on Wynn Resorts or Las Vegas Sands right now.
Jim Cramer's 'Mad Money' Recap: Wall Street Is Confused
at The Street - Thu Mar 27, 7:26PM CDT
Cramer says the market is so full of confusing cross-currents it has him wondering if there's something big around the corner.
Insys Therapeutics to Present at the 13th Annual Needham Healthcare Conference
Marketwire - Wed Mar 19, 3:30PM CDT
Insys Therapeutics, Inc. (NASDAQ: INSY) today announced that the Company will present at the 13th Annual Needham Healthcare Conference on April 8 - 9, 2014 at the Westin Grand Central in New York City.
Insys Therapeutics (INSY) Showing Signs Of A Dead Cat Bounce Today
at The Street - Tue Mar 18, 9:55AM CDT
Trade-Ideas LLC identified Insys Therapeutics (INSY) as a "dead cat bounce" (down big yesterday but up big today) candidate
Should You Believe Tesaro's Hype?
Todd Campbell, The Motley Fool - Motley Fool - Mon Mar 17, 1:30PM CDT
Tesaro's CEO Lonnie Moulder is likely unfazed by the company's eye popping volatility over the past few months. Moulder has a long history of navigating the inherent booms and busts common in emerging biotech. Luckily for Moulder's investors,...
Insider Trading Alert - INSY, RAI And ACGL Traded By Insiders
at The Street - Fri Mar 14, 10:45AM CDT
Stocks with insider trader activity include INSY, RAI and ACGL
Financial Results, FDA Reviews, and Share Price Movements - Analyst Notes on Insys, Oxygen Biotherapeutics, Acorda, Air Methods, and AcelRx
PR Newswire - Fri Mar 07, 7:00AM CST
Today, Analysts Review released its analysts' notes regarding INSYS Therapeutics, Inc. (NASDAQ: INSY), Oxygen Biotherapeutics, Inc. (NASDAQ: OXBT), Acorda Therapeutics, Inc. (NASDAQ: ACOR), Air Methods Corp. (NASDAQ: AIRM), and AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Has Insys Run Too Far Too Fast?
Todd Campbell, The Motley Fool - Motley Fool - Wed Mar 05, 5:30PM CST
Few investments have paid off as handsomely as Insys this past year. The company, which gets most of its sales from breakthrough pain treatment Subsys, has soared more than 700% in the past year. The excitement surrounding Insys has come as...
INSYS Therapeutics (INSY) Soars: Stock Adds 21.7% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Mar 05, 8:39AM CST
INSYS Therapeutics, Inc. was a big mover last session, as its shares rose just nearly 22% on the day.
Insys Therapeutics: Today's Big Biotech Winner
David Williamson, The Motley Fool - Motley Fool - Tue Mar 04, 6:52PM CST
Shares of Insys Therapeutics rose 20% today, after the company posted strong second-quarter results for its cancer-related pain medicine, Subsys. After operating at a loss last year, the 38% sales growth of the drug this year helped propel Insys...
Insys Q4 Earnings Beat Street; Stock Hits High
at Investor's Business Daily - Tue Mar 04, 2:44PM CST
Biotech Insys Therapeutics (INSY) soundly beat analysts' Q4 estimates and announced a stock split Tuesday, sending shares soaring more than 20% to a new high on the stock market today. The company's revenue totaled $40 million in the quarter vs. just...
Stocks Rally As Ukraine Fears Ebb; China Names Lead
at Investor's Business Daily - Tue Mar 04, 2:09PM CST
Fears of a conflict in Ukraine subsided -- at least for a day -- on Wall Street as stocks raced out of the gate and held strong gains with a little over one hour remaining in the session. The Nasdaq gained 1.6%, good for another 52-week high. The S&P...
Why Insys Therapeutics, Inc. Shares Skyrocketed
Sean Williams, The Motley Fool - Motley Fool - Tue Mar 04, 12:23PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Insys Therapeutics , a biopharmaceutical...
